ʻO Dabigatran Etexilate Mesylate
wehewehe
ʻO Dabigatran etexilate mesylate (BIBR 1048MS) kahi mea hoʻohana waha o Dabigatran.Loaʻa ka Dabigatran etexilate mesylate i nā hopena anticoagulant a hoʻohana ʻia no ka prophylaxis o ka venousthromboembolism a me ka hahau ma muli o ka fibrillation atrial.
Ka hope
Hōʻike: IC50 Waiwai: 4.5nM (Ki);10nM(Thrombin-induced platelet aggregation) [1] ʻO Dabigatran he mea hiki ke hoʻohuli a koho, pololei thrombin inhibitor (DTI) e hele ana i ka hoʻomohala hoʻomohala holomua e like me kāna prodrug hoʻoikaika waha, dabigatran etexilate.in vitro: Dabigatran selectively and reversibly inhibited human thrombin (Ki: 4.5 nM) a me ka thrombin-induced platelet aggregation (IC(50): 10 nM), oiai e hoike ana aole he hopena pale i na mea hooulu platelet e ae. Thrombin generation in platelet -poor plasma (PPP), i ana e like me ka endogenous thrombin potential (ETP) i inhibited concentration-dependently (IC(50): 0.56 microM).Ua hōʻike ʻo Dabigatran i nā hopena anticoagulant e hilinaʻi nui ana i nā ʻano like ʻole i loko o ka vitro, e pālua i ka manawa o ka thromboplastin partial (aPTT), ka manawa prothrombin (PT) a me ka manawa o ka ecarin clotting (ECT) i loko o ka PPP kanaka ma ka nui o 0.23, 0.83 a me 0.18 microM. 1].in vivo: Ua hoʻolōʻihi ʻia ʻo Dabigatran i ka nui o ka aPTT ma hope o ka lawelawe intravenous i nā ʻiole (0.3, 1 a me 3 mg / kg) a me nā monkey rhesus (0.15, 0.3 a me 0.6 mg / kg).Ua ʻike ʻia nā hopena anticoagulant e pili ana i ka dosis a me ka manawa me ka dabigatran etexilate i hāʻawi waha ʻia i nā ʻiole ʻike (10, 20 a me 50 mg / kg) a i ʻole rhesus monkeys (1, 2.5 a i ʻole 5 mg / kg), me nā hopena kiʻekiʻe loa i ʻike ʻia ma waena o 30 a me 120. min ma hope o ka lawelawe ʻana, i kēlā me kēia [1].ʻO ka poʻe maʻi i mālama ʻia me ka dabigatran etexilate ua liʻiliʻi ka liʻiliʻi o nā hahau ischemic (3.74 dabigatran etexilate vs 3.97 warfarin) a me ka liʻiliʻi o nā hemorrhages intracranial hui pū ʻia a me nā maʻi hemorrhagic (0.43 dabigatran etexilate vs 0.99 warfarin) no 100 mau makahiki maʻi.Ka ho'āʻo hoʻokolohua: He loiloi o nā Pharmacokinetics a me Pharmacodynamics o Oral Dabigatran Etexilate i nā maʻi Hemodialysis.Māhele1
Waihona
| Pauda | -20°C | 3 makahiki |
| 4°C | 2 makahiki | |
| I ka solvent | -80°C | 6 mahina |
| -20°C | 1 mahina |
ʻO ka hoʻokolohua lapaʻau
| Helu NCT | Kākoʻo | Kūlana | Lā Hoʻomaka | Māhele |
| NCT02170792 | ʻO Boehringer Ingelheim | Ola ola | Pepeluali 2001 | Māhele 1 |
| NCT02170974 | ʻO Boehringer Ingelheim | Ola ola | Iulai 2004 | Māhele 1 |
| NCT02170831 | ʻO Boehringer Ingelheim | Ola ola | Mei 1999 | Māhele 1 |
| NCT02170805 | ʻO Boehringer Ingelheim | Ola ola | ʻApelila 2001 | Māhele 1 |
| NCT02170610 | ʻO Boehringer Ingelheim | Ola ola | Malaki 2002 | Māhele 1 |
| NCT02170909 | ʻO Boehringer Ingelheim | Ola ola | Kekemapa 2004 | Māhele 1 |
| NCT02171000 | ʻO Boehringer Ingelheim | Ola ola | ʻApelila 2005 | Māhele 1 |
| NCT02170844 | ʻO Boehringer Ingelheim | Ola ola | Iune 2004 | Māhele 1 |
| NCT02170584 | ʻO Boehringer Ingelheim | Ola ola | Ianuali 2001 | Māhele 1 |
| NCT02170935 | ʻO Boehringer Ingelheim | ʻO ka Thromboembolism Venous | ʻApelila 2002 | Māhele 2 |
| NCT02170636 | ʻO Boehringer Ingelheim | Ola ola | Ianuali 2002 | Māhele 1 |
| NCT02170766 | ʻO Boehringer Ingelheim | Ola ola | ʻOkakopa 2000 | Māhele 1 |
| NCT02171442 | ʻO Boehringer Ingelheim | Ola ola | ʻApelila 2002 | Māhele 1 |
| NCT02170896 | ʻO Boehringer Ingelheim | Ola ola | ʻOkakopa 2001 | Māhele 1 |
| NCT02173730 | ʻO Boehringer Ingelheim | Ola ola | Nowemapa 2002 | Māhele 1 |
| NCT02170623 | ʻO Boehringer Ingelheim | Ola ola | Pepeluali 2002 | Māhele 1 |
| NCT02170116 | ʻO Boehringer Ingelheim | Ola ola | Nowemapa 1998 | Māhele 1 |
| NCT02170597 | ʻO Boehringer Ingelheim | Ola ola | ʻAukake 2003 | Māhele 1 |
| NCT01225822 | ʻO Boehringer Ingelheim | ʻO ka Thromboembolism Venous | Nowemapa 2002 | Māhele 2 |
| NCT02170701 | ʻO Boehringer Ingelheim | ʻO ka Thromboembolism Venous | ʻOkakopa 2000 | Māhele 2 |
| NCT02170740 | ʻO Boehringer Ingelheim | Ola ola | Nowemapa 1999 | Māhele 1 |
| NCT02170922 | ʻO Boehringer Ingelheim | Ola ola | Iulai 1999 | Māhele 1 |
ʻO ke kinona
Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.
Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.
Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.
Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.
Kolea Countec Bottled Packaging Line
ʻO Taiwan CVC Bottled Packaging Line
ʻO Italia CAM Board Packaging Line
Mekini Fette Compacting German
ʻO Iapana Viswill Tablet ʻIke
Keena Mana DCS
